D L Carlson Investment Group Inc. grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,925 shares of the biopharmaceutical company’s stock after buying an additional 3,637 shares during the period. D L Carlson Investment Group Inc.’s holdings in Bristol-Myers Squibb were worth $2,286,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Financial Gravity Wealth Inc. acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $26,000. Capital Financial Planning LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Well Done LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $30,000. Trust Department MB Financial Bank N A acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $32,000. Finally, Riverview Trust Co acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $33,000. 77.54% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the company. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, March 5th. BMO Capital Markets lifted their target price on Bristol-Myers Squibb to $62.00 and gave the company an “outperform” rating in a report on Wednesday, March 20th. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Saturday, May 4th. UBS Group reduced their target price on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a report on Thursday, June 13th. Finally, JPMorgan Chase & Co. assumed coverage on Bristol-Myers Squibb in a research note on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $56.34.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The company had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the firm posted $0.94 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 14.0% compared to the same quarter last year. As a group, analysts expect that Bristol-Myers Squibb Co will post 4.2 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Wednesday, July 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.62%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
In related news, Director Theodore R. Samuels II bought 5,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was bought at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the purchase, the director now directly owns 27,000 shares in the company, valued at approximately $1,276,830. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares of the company’s stock, valued at $145,818.96. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.